SCHEMBL17560992

SCHEMBL17560992

Nc1nc(NN=Cc2ccc(F)cc2)cc(NN=Cc2ccc(F)cc2)n1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.57
HPGD P15428 2/20 0.57
RAB9A P51151 8/20 0.55
MAPK1 P28482 1/20 0.55
NPSR1 Q6W5P4 2/20 0.51
MAPT P10636 6/20 0.50
GAA P10253 4/20 0.48
ATM Q13315 1/20 0.48
NPC1 O15118 7/20 0.47
PKM P14618 2/20 0.47
LMNA P02545 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MPO P05164 1/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 2/20 0.42
GLA P06280 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17560989 1.00 SMN1; SMN2 (0.57) SMN1; SMN2HPGDRAB9AMAPK1NPSR1
SCHEMBL17561016 0.84 SMN1; SMN2 (0.51) SMN1; SMN2HPGDRAB9AMAPK1NPSR1
SCHEMBL17561018 0.84 SMN1; SMN2 (0.51) SMN1; SMN2HPGDRAB9AMAPK1NPSR1
SCHEMBL16224345 0.84 MAPT (0.57) SMN1; SMN2HPGDRAB9ANPSR1MAPT
SCHEMBL16212197 0.84 SMN1; SMN2 (0.64) SMN1; SMN2HPGDRAB9AMAPK1NPSR1
SCHEMBL17560833 0.84 MAPT (0.57) SMN1; SMN2HPGDRAB9ANPSR1MAPT
SCHEMBL16212199 0.84 SMN1; SMN2 (0.64) SMN1; SMN2HPGDRAB9AMAPK1NPSR1
SCHEMBL16224338 0.84 SMN1; SMN2 (0.57) SMN1; SMN2HPGDRAB9AMAPTGAA
SCHEMBL16224305 0.84 SMN1; SMN2 (0.57) SMN1; SMN2HPGDRAB9ANPSR1MAPT
SCHEMBL17560933 0.84 SMN1; SMN2 (0.57) SMN1; SMN2HPGDRAB9ANPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3960729-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS Neoculi Pty Ltd (AU) 2022-03-02 EP claimed
US-10562880-B2 Methods for treating protozoan infections NEOCULI PTY LTD. (AU) 2020-02-18 US claimed
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2019-10-31 US claimed
US-10370341-B2 Compounds and methods of treating infections NEOCULI PTY LTD (AU) 2019-08-06 US claimed
US-10253002-B2 Compounds and methods of treating infections NEOCULI PTY LTD (AU) 2019-04-09 US claimed
US-20190084941-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS NEOCULI PTY LTD (AU) 2019-03-21 US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
EP-3188722-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS Neoculi Pty Ltd (AU) 2017-07-12 EP claimed
WO-2016033635-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2016-03-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190084941-A1 COMPOUNDS AND METHODS OF TREATING INFECTIONS ELANE, IL1A, IL1B SMN1; SMN2 3440/4885HPGD 261/4885RAB9A 3788/4885
US-10370341-B2 Compounds and methods of treating infections ELANE, IL1A, IL1B SMN1; SMN2 3440/4885HPGD 261/4885RAB9A 3788/4885
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS SMN1; SMN2 3002/4885HPGD 232/4885RAB9A 3198/4885
US-20190330178-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS SMN1; SMN2 3002/4885HPGD 232/4885RAB9A 3198/4885
US-10562880-B2 Methods for treating protozoan infections DPM1, ABCB11, PIGS SMN1; SMN2 3002/4885HPGD 232/4885RAB9A 3198/4885
US-10253002-B2 Compounds and methods of treating infections ELANE, IL1A, IL1B SMN1; SMN2 3440/4885HPGD 261/4885RAB9A 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.